Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

Required: IL3RA overexpression (≥20% of leukemic cells expressing CD123 at any point in the course of disease)

Participants with CD123+ AML (defined as ≥20% of leukemic cells expressing CD123 at any point in the course of disease)

Must have received: standard or life-extending therapies

for whom all standard or life-extending therapies have failed and for whom no potentially curative therapies are available or who are intolerant to such therapies

Cannot have received: allogeneic stem cell transplantation

Exception: allowed if >2 months prior and no GvHD requiring systemic immunosuppressive therapy

Allogeneic stem cell transplantation within last 2 months or GvHD requiring systemic immunosuppressive therapy

Cannot have received: gene modified cell products

Prior treatment with gene modified cell products

Cannot have received: investigational drug substance or experimental therapy

Treatment with any investigational drug substance or experimental therapy within 4 weeks or 5 half-lives (whichever is shorter) of the substance prior to lymphodepletion

Cannot have received: anti-leukemic therapy

Treatment with anti-leukemic therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to lymphodepletion

Cannot have received: checkpoint inhibitor

Use of checkpoint inhibitors within 5 half-lives of the specific drug